Cover Image

Comparative clinical-related outcomes of Chinese patent medicines for cardiac hypertrophy: A systematic review and network meta-analysis of randomized clinical trials

Background: Persistent pathological cardiac hypertrophy has been associated with increased risk of heart failure and even sudden death. Multiple Chinese patent medicines (CPMs) have gained attention as alternative and complementary remedies due to their high efficiency and few side effects. However,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tianqi Zhang (Author), Haoyang Xu (Author), Dong Zhen (Author), Danni Fu (Author), Ming Zhao (Author), Chengxi Wei (Author), Xue Bai (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical practice guidelines of Chinese patent medicine in China: A critical review
by: Jian-xin Wang, et al.
Published: (2024)

Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment
by: Runzhi Zhang, et al.
Published: (2019)

Energy Metabolism in Exercise-Induced Physiologic Cardiac Hypertrophy
by: Kefa Xiang, et al.
Published: (2020)

Efficacy and Safety of Chinese Patent Medicine Combined With Oseltamivir in Treatment of Children With Influenza: A meta-Analysis
by: Nai-fan Duan, et al.
Published: (2021)

Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis
by: Jiarong Liu, et al.
Published: (2022)

Comparative efficacy of Chinese patent medicines for non-alcoholic fatty liver disease: A network meta-analysis
by: Lihui Zhang, et al.
Published: (2023)

Comparative efficacy, safety and cost of oral Chinese patent medicines for rheumatoid arthritis: a Bayesian network meta-analysis
by: Dan Zhang, et al.
Published: (2020)

Network pharmacology integrated with experimental validation to elucidate the mechanisms of action of the Guizhi-Gancao Decoction in the treatment of phenylephrine-induced cardiac hypertrophy
by: Kaijing Yang, et al.
Published: (2024)

Comparative efficacy of Chinese patent medicines in patients with carotid atherosclerotic plaque: a Bayesian network meta− analysis
by: Wenquan Su, et al.
Published: (2023)

Traditional Chinese Medicine Intervenes in Vascular Dementia: Traditional Medicine Brings New Expectations
by: Xue Bai, et al.
Published: (2021)

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis
by: Li Jiang, et al.
Published: (2022)

The interplay of personality traits, anxiety, and depression in Chinese college students: a network analysis
by: Tianqi Yang, et al.
Published: (2023)

Efficacy and safety of Chinese herbal medicine for pneumonia convalescence in children: A systematic review and meta-analysis
by: Jian-Ning Guo, et al.
Published: (2022)

Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy
by: G. Ian Gallicano, et al.
Published: (2022)

Ganoderma lucidum polysaccharides attenuates pressure-overload-induced pathological cardiac hypertrophy
by: Changlin Zhen, et al.
Published: (2023)

Patented technologies for schistosomiasis control and prevention filed by Chinese applicants
by: Yan-Hong Xiong, et al.
Published: (2021)

Thiopental sodium loaded solid lipid nano-particles attenuates obesity-induced cardiac dysfunction and cardiac hypertrophy via inactivation of inflammatory pathway
by: Canzhan Zhu, et al.
Published: (2020)

Evaluation of cardiac hypertrophy in the setting of sudden cardiac death
by: Kristopher S. Cunningham, et al.
Published: (2019)

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
by: Yan Chen, et al.
Published: (2022)

Circular RNAs in the regulation of cardiac hypertrophy
by: Siyi Wu, et al.
Published: (2022)

Editorial: Cardiac Hypertrophy: From Compensation to Decompensation and Pharmacological Interventions
by: Ya Liu, et al.
Published: (2021)

Exploration of the mechanism of Traditional Chinese Medicine for anxiety and depression in patients with diarrheal irritable bowel syndrome based on network pharmacology and meta-analysis
by: Chen Bai, et al.
Published: (2024)

Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis
by: Jie Zhao, et al.
Published: (2022)

Comparative efficacy of different Chinese patent medicines in preventing restenosis after percutaneous coronary intervention: a systematic review and Bayesian network meta-analysis of randomized clinical trials
by: Jiasai Fan, et al.
Published: (2024)

Analysis of Clinical Efficacy of Traditional Chinese Medicine in Recovery Stage of Stroke: A Systematic Review and Meta-Analysis
by: Xue Zhang, et al.
Published: (2020)

Comparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials
by: Qun Wang, et al.
Published: (2024)

Network analysis of affect, emotion regulation, psychological capital, and resilience among Chinese males during the late stage of the COVID-19 pandemic
by: Zhihua Guo, et al.
Published: (2023)

Role of microRNAs in cardiac hypertrophy, myocardial fibrosis and heart failure
by: De-li Dong, et al.
Published: (2011)

Andrographolide contributes to the attenuation of cardiac hypertrophy by suppressing endoplasmic reticulum stress
by: Qingxin Tian, et al.
Published: (2023)

An Efficacy and Feasibility Analysis of Chinese Patent Medicine Combined With Letrozole in the Treatment of Women With Ovulation Disorders: A Network Meta-Analysis
by: Jing-Yan Zhu, et al.
Published: (2021)

Si-Miao-Yong-An Decoction Protects Against Cardiac Hypertrophy and Dysfunction by Inhibiting Platelet Aggregation and Activation
by: Congping Su, et al.
Published: (2019)

Raf-mediated cardiac hypertrophy in adult Drosophila
by: Lin Yu, et al.
Published: (2013)

Guideline on treating community-acquired pneumonia with Chinese patent medicines
by: Minghang Wang, et al.
Published: (2023)

Wogonin Inhibits Cardiac Hypertrophy by Activating Nrf-2-Mediated Antioxidant Responses
by: Xiaowen Shi, et al.
Published: (2021)

Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway
by: Tingwei Zhao, et al.
Published: (2021)

Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Xiao-Wen Zhang, et al.
Published: (2022)

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review
by: Liangyu Cui, et al.
Published: (2024)

Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines
by: Ying Wu, et al.
Published: (2021)

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
by: Peiying Huang, et al.
Published: (2022)

Dendrobium candidum aqueous extract attenuates isoproterenol-induced cardiac hypertrophy through the ERK signalling pathway
by: Yuan-Yuan Cao, et al.
Published: (2020)